160 related articles for article (PubMed ID: 34178295)
1. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
[No Abstract] [Full Text] [Related]
2. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
3. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631
[TBL] [Abstract][Full Text] [Related]
5. Cell-Based Gene Therapy for b-Thalassemia.
Arya Y; Sahi PK
Indian Pediatr; 2023 Apr; 60(4):313-316. PubMed ID: 37002845
[TBL] [Abstract][Full Text] [Related]
6. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.
Whitney D; Shestopalov I; Fincker M; d'Anjou M; Kral K; Gayron M; Pierciey FJ; Colvin RA
Mol Ther Methods Clin Dev; 2023 Dec; 31():101155. PubMed ID: 38074412
[No Abstract] [Full Text] [Related]
7. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
10. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
11. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.
Alshamsi S; Hamidi S; Narci HO
BMC Health Serv Res; 2022 Mar; 22(1):304. PubMed ID: 35248046
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
14. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
Leung VC; Pechlivanoglou P; Chew HF; Hatch W
Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
16. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
17. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA
Watada H; Sakamaki H; Yabe D; Yamamoto F; Murata T; Hanada K; Hirase T; Okamura T
Diabetes Ther; 2020 Aug; 11(8):1721-1734. PubMed ID: 32557283
[TBL] [Abstract][Full Text] [Related]
19. Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.
Shafie AA; Wong JHY; Ibrahim HM; Mohammed NS; Chhabra IK
Orphanet J Rare Dis; 2021 Apr; 16(1):157. PubMed ID: 33827621
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
